Core Viewpoint - HBN's parent company, Shenzhen Hujia Technology (Group) Co., Ltd., has submitted a listing application to the Hong Kong Stock Exchange, with Morgan Stanley and CICC as joint sponsors. The funds raised will primarily be used for R&D, product innovation, enhancing production capacity, improving office environments, and expanding digital operations and marketing efforts [1][14]. Financial Performance - In 2023, 2024, and the first three quarters of 2025, HBN achieved revenues of RMB 19.48 billion, RMB 20.8 billion, and RMB 15.14 billion, with year-on-year growth rates of 6.9% and 10.2% for 2024 and 2025, respectively. Net profits for the same periods were RMB 38.83 million, RMB 129.14 million, and RMB 144.53 million, reflecting significant growth of 232.5% and 190.3% in 2024 and 2025 [4][17]. Marketing and R&D Expenditure - Approximately 60% of HBN's revenue is allocated to marketing, while R&D investment remains low at around 3%, raising concerns about the sustainability of its business model. In 2023, 2024, and 2025, marketing expenses were RMB 12.68 billion, RMB 12.38 billion, and RMB 8.7 billion, accounting for 65.1%, 59.4%, and 57.6% of total revenue, respectively. In contrast, R&D expenditures were only RMB 0.66 billion, RMB 0.58 billion, and RMB 0.4 billion [6][21][22]. Product and Brand Dependency - HBN's product lines include both improvement and stabilization skincare products, with a total of 36 SKUs priced between RMB 129 and RMB 689. The company heavily relies on its single brand, HBN, for revenue generation, which poses risks if consumer preferences shift or if the brand faces reputational issues [4][10][17]. Sales Channel Concentration - HBN's sales are predominantly online, with online revenue accounting for 98.6%, 97.7%, and 95.1% in 2023, 2024, and 2025, respectively. In contrast, offline sales are minimal, representing only 1.4% and 2.3% of total revenue in 2023 and 2024. This heavy reliance on online channels may limit the company's ability to reach customers who prefer in-store experiences [11][24]. Industry Challenges - The skincare industry faces significant challenges, including product homogenization and intense price competition, which can undermine profitability. The heavy focus on marketing over R&D may hinder innovation and long-term growth, making companies vulnerable to market fluctuations and consumer trends [9][22].

Core Viewpoint - Shandong Huawutang Cosmetics Co., Ltd. has submitted its prospectus to the Hong Kong Stock Exchange, aiming to become the first domestic personal care stock in Hong Kong, with funds raised primarily for channel development, marketing, brand building, and enhancing R&D capabilities [1][13]. Financial Performance - The company has shown significant revenue growth, with a 76.7% year-on-year increase in revenue to 1.895 billion RMB in the first three quarters of 2025, and a 197.41% increase in adjusted net profit to 148 million RMB [4][17]. - Revenue figures for 2023, 2024, and the first nine months of 2025 are 1.199 billion RMB, 1.499 billion RMB, and 1.895 billion RMB, respectively, with year-on-year growth rates of 25% and 76.7% for 2024 and 2025 [4][17]. Marketing Strategy - The company's growth is heavily reliant on marketing, particularly through celebrity endorsements, which have significantly boosted brand visibility and sales conversion [14][20]. - Marketing expenses for 2023, 2024, and the first nine months of 2025 were 637 million RMB, 677 million RMB, and 896 million RMB, accounting for 53.2%, 45.2%, and 47.3% of total revenue, respectively [20][23]. Product Performance - The company has experienced varied growth across its product lines, with body care and hair care products showing substantial increases, while facial care products have only seen single-digit growth [4][9]. - For the first three quarters of 2025, body care, hair care, and facial care products generated revenues of 791 million RMB, 482 million RMB, and 463 million RMB, with year-on-year growth rates of 60.7%, 496.1%, and 3.4%, respectively [4][18]. R&D and Channel Strategy - R&D expenditure has been relatively low, with rates dropping from 2.4% in 2023 to 1.5% in the first nine months of 2025, indicating a heavy focus on marketing over product innovation [10][23]. - The company relies heavily on online sales channels, with online revenue accounting for 85.7%, 75.9%, and 76.3% of total revenue in 2023, 2024, and the first nine months of 2025, respectively [12][23].

Core Insights - The skincare and daily chemical industry in A-share listed companies shows a persistent trend of high gross margins and low net margins, with over 80% of companies having a gross margin above 50% and more than half having a net margin below 10% [1][2] Group 1: Financial Performance - In the first half of 2025, the top three companies by gross margin are Jinbo Biological (90.68%), Fulejia (81.47%), and Beitaini (76.01%) [2] - Despite high gross margins, over half of the selected companies have net margins below 10%, with Jinbo Biological, Fulejia, and Proya leading in net margins at 45.5%, 26.61%, and 15.41% respectively [2] Group 2: Marketing and Expenses - The high gross margin and low net margin phenomenon is closely linked to the significant marketing expenditures in the industry, with companies like Marubi Biological having a sales expense ratio as high as 56.5% [1][3] - Many companies in the skincare and daily chemical sector are spending over 40% of their revenue on marketing, indicating a highly competitive marketing environment [3] Group 3: Research and Development - The investment in R&D is significantly lower than marketing expenditures, with Marubi Biological's R&D expense ratio being only 2.3% compared to its high sales expense ratio [3] - The focus on marketing over R&D has led to severe product homogeneity, limiting innovation and the ability to meet consumer skincare needs effectively [3]

Core Insights - The skincare and daily chemical industry in A-share listed companies has shown improvement in inventory status as of the first half of 2025, with only 6 out of 14 selected companies experiencing an increase in inventory scale [1] - Among the selected companies, only 5 have inventory turnover days below 90 days, indicating potential inefficiencies in inventory management for the remaining 9 companies [1] - The inventory turnover efficiency indicators for the industry are concerning, with 6 companies showing prolonged inventory turnover days, which may suggest risks of product obsolescence or slow sales [1] Inventory Analysis - In the first half of 2025, the inventory situation improved for the skincare and daily chemical listed companies, with a notable increase in inventory scale for Jinbo Biological, which had the highest year-on-year growth [1] - Only 5 companies, including Jiaheng Home, Qingsong Co., Proya, Shanghai Jahwa, and Lafang, maintained inventory turnover days below 90, while the other 9 exceeded this threshold [1] - Companies such as Huaxi Biological and Jinbo Biological are among those with longer inventory turnover days, raising concerns about their inventory management practices [1] Market Implications - The prolonged inventory turnover days across several companies may indicate a longer time frame from production to sale, potentially leading to product expiration risks [1] - The overall inventory turnover efficiency in the skincare and daily chemical sector is not optimistic, highlighting a need for companies to improve their inventory management strategies [1]

Core Insights - The skincare and daily chemical industry in A-share listed companies has shown improvements in inventory levels as of the first half of 2025, with only 6 out of 14 selected companies experiencing an increase in inventory size [1][2] Inventory Size Analysis - Jinbo Biological had the largest year-on-year increase in inventory, reaching 153 million yuan, a growth of 116.79% compared to the first half of 2024 [1][2] - Kesheng Co. also saw significant growth, with inventory at 628 million yuan, up 40.87% year-on-year [1][2] - Other companies with notable inventory increases include Marubi Biological (35.91%), Chuang'er Biological (34.02%), and Jiaheng Home Care (31.39%) [2] Inventory Turnover Days - Among the 14 selected companies, only 5 had inventory turnover days below 90 days, indicating efficient inventory management [3] - Companies with inventory turnover days exceeding 180 days include Huaxi Biological (331.61 days), Jinbo Biological (280.81 days), Kesheng Co. (230.92 days), and Betaini (195.78 days) [3][4] - The overall inventory turnover efficiency has not improved, with 8 companies experiencing longer turnover days, particularly those exceeding 180 days [3] Year-on-Year Changes in Inventory Turnover Days - Huaxi Biological's turnover days increased by 13.34%, Jinbo Biological by 15.66%, Kesheng Co. by 115.83%, and Betaini by 0.54% [3][4] - Notably, the turnover days for LaFang Home Care decreased by 27.40%, and Shanghai Home Care by 15.74%, indicating some companies are managing their inventory more effectively [4]

Core Viewpoint - The skincare and daily chemical industry in A-share listed companies has shown improvements in inventory levels for the first half of 2025, with only six out of fourteen selected companies experiencing an increase in inventory size [1][2]. Inventory Scale Analysis - In the first half of 2025, Jinbo Biological had the largest year-on-year increase in inventory, reaching 153 million yuan, a growth of 116.79% [2]. - Kesheng Co. also saw significant inventory growth, with a total of 628 million yuan, marking a 40.87% increase [2]. - Other companies with notable inventory increases include Marubi Biological (35.91%), Chuang'er Biological (34.02%), and Jiaheng Home Care (31.39%) [2]. Inventory Turnover Days - Among the fourteen selected companies, only five had inventory turnover days below 90 days, indicating efficient inventory management [2]. - Companies with inventory turnover days exceeding 180 days include Huaxi Biological (331.61 days), Jinbo Biological (280.81 days), Kesheng Co. (230.92 days), and Beitaini (195.78 days) [2][4]. - The overall inventory turnover efficiency in the industry is concerning, with six companies showing improvement while eight companies experienced longer turnover days [3]. Year-on-Year Changes in Inventory Turnover Days - Huaxi Biological's inventory turnover days increased by 13.34%, reaching 331.61 days [4]. - Jinbo Biological's turnover days rose by 15.66% to 280.81 days [4]. - Kesheng Co. saw a dramatic increase of 115.83% in turnover days, reaching 230.92 days [4]. - Other companies like Fushijia and Shanghai Jahwa also reported changes in turnover days, with Fushijia increasing by 31.52% [4].

Core Insights - The skincare and daily chemical industry in A-shares has shown a high gross profit margin but low net profit margin, with over 80% of companies having a gross profit margin above 50% and more than half having a net profit margin below 10% [1][4] - The significant gap between gross and net profit margins is attributed to high sales expenses, which consume profits, with Marubi Biological's sales expense ratio reaching 56.5%, making it the highest in the industry [1][6] Financial Performance - The top three companies by gross profit margin in the first half of 2025 are Jinbo Biological (90.68%), Fulejia (81.47%), and Beitaini (76.01%) [2] - Only four companies reported a gross profit margin below 50%, namely Lafang, Kesi, Qingsong, and Jiaheng, with margins of 49.26%, 32.05%, 17.51%, and 14.98% respectively [2] Profitability Analysis - Despite high gross profit margins, over half of the selected companies have net profit margins below 10%, with Jinbo Biological, Fulejia, and Polaroid leading in net profit margins at 45.5%, 26.61%, and 15.41% respectively [4] - Jiaheng, Lafang, and Qingsong have low net profit margins of -6.26%, 1.58%, and 2.66% respectively [4] Marketing and R&D Expenditure - The high marketing expenses in the industry are closely linked to the high gross and low net profit margins, with many companies spending over 40% of their revenue on marketing [6][9] - Marubi Biological's sales expense ratio is 56.5%, while its R&D expense ratio is only 2.3%, indicating a heavy reliance on marketing over research and development [8] Industry Challenges - The focus on marketing over R&D has led to severe product homogeneity, limiting innovation and hindering brand development [8] - The industry faces ongoing price wars and promotional activities that further erode profitability, creating a vicious cycle [9] - Companies need to balance marketing and R&D expenditures to transition from a marketing-driven to a product-driven approach [9]

Core Insights - The skincare and daily chemical industry in A-shares has shown a high gross profit margin but low net profit margin, with over 80% of companies having a gross profit margin above 50% and more than half having a net profit margin below 10% [1][4] - The significant gap between gross and net profit margins is attributed to high sales expenses, which consume profits, with Marubi Biological's sales expense ratio reaching 56.5%, making it the highest in the industry [1][6] Group 1: Financial Performance - The top three companies by gross profit margin in the first half of 2025 are Jinbo Biological (90.68%), Fulejia (81.47%), and Beitaini (76.01%) [2] - Only four companies reported a gross profit margin below 50%, namely Lafang, Kesi, Qingsong, and Jiaheng, with margins of 49.26%, 32.05%, 17.51%, and 14.98% respectively [2] - The leading companies in net profit margin are Jinbo Biological (45.5%), Fulejia (26.61%), and Polaroid (15.41%), while Jiaheng, Lafang, and Qingsong have low margins of -6.26%, 1.58%, and 2.66% respectively [4] Group 2: Marketing and R&D Expenditure - The high marketing expenses in the industry are closely linked to the high gross profit but low net profit, with many companies spending over 40% of their revenue on marketing [6][9] - Marubi Biological's sales expense ratio is 56.5%, while its R&D expense ratio is only 2.3%, indicating a heavy reliance on marketing over research and development [8] - The focus on marketing over R&D has led to severe product homogenization, limiting innovation and hindering brand development [8][9] Group 3: Industry Challenges - The industry faces challenges in balancing marketing and R&D expenditures, with a need to shift from marketing-driven to product-driven strategies [9]

Core Insights - The skincare and daily chemical industry in A-shares has shown a high gross profit margin but low net profit margin, with over 80% of companies having a gross profit margin above 50% and more than half having a net profit margin below 10% [1][4] - The significant gap between gross and net profit margins is attributed to high sales expenses, which consume profits, with Marubi Biological's sales expense ratio reaching 56.5%, making it the highest in the industry [1][6] Financial Performance - The top three companies in terms of gross profit margin for the first half of 2025 are Jinbo Biological (90.68%), Fulejia (81.47%), and Beitaini (76.01%) [2] - Only four companies reported a gross profit margin below 50%, with figures of 49.26% for Lafang, 32.05% for Kesi, 17.51% for Qingsong, and 14.98% for Jiaheng [2] Marketing and R&D Expenditure - The industry is characterized by high marketing expenditures, with many companies spending over 40% of their revenue on marketing, leading to a focus on brand marketing over product development [6][9] - Marubi Biological's sales expense ratio is 56.5%, while its R&D expense ratio is only 2.3%, indicating a heavy reliance on marketing rather than innovation [8] Industry Challenges - The heavy emphasis on marketing has resulted in severe product homogeneity, limiting true innovation and hindering brand development [8] - The industry faces ongoing price wars and promotional activities that further erode profitability, creating a vicious cycle [9] - Companies must find a balance between marketing and R&D expenditures to transition from a marketing-driven approach to a product-driven strategy [9]

Core Insights - The 67th China (Shanghai) International Beauty Expo successfully showcased the vitality and potential of the beauty industry, emphasizing resilience, innovation, and intelligence in development [1][2] Group 1: Event Overview - The expo covered an exhibition area of 150,000 square meters, featuring over 1,800 exhibitors from more than 68 countries and regions, displaying over 10,000 selected product categories [2] - The event attracted significant foot traffic and facilitated vibrant business exchanges, highlighting the robust market activity within the beauty sector [2] Group 2: Global Expansion - The expo aimed to build a new ecosystem for diverse cooperation in the beauty industry, establishing an efficient global communication platform for sourcing and sales [3] - It gathered professional buyers from various channels, including traditional retailers and new e-commerce trends, showcasing international exhibitors from countries like South Korea, Japan, the USA, and Canada [3] - Plans for 2025 include the addition of the "Indonesia International Beauty Expo" and "Vietnam International Beauty Expo," supporting Chinese beauty brands in expanding overseas [3] Group 3: Industry Innovation - The expo focused on industry logic, uniting upstream and downstream brand forces, with new products covering multiple fields, enhancing brand competitiveness and driving technological upgrades [4] - AI technology in beauty attracted attention, while several medical beauty brands accelerated their entry into the daily skincare market [4] - The event highlighted the "Matthew Effect" in the daily chemical sector, with leading brands leveraging resources to enter professional channels [4] Group 4: Future Trends - The expo outlined a development blueprint for the beauty industry through a systematic approach of summits, activities, and special exhibitions, providing forward-looking insights [5] - Over 50 special events were held during the expo, covering topics such as beauty, health, and e-commerce, enhancing the industry's outreach and impact [5] - The event featured 15+ themed exhibition areas, showcasing innovations in professional technology, AI applications, and cross-industry segments [5] Group 5: Looking Ahead - The beauty expo is set to embark on a new journey, focusing on domestic demand and actively exploring new growth areas for Chinese beauty brands [6] - The next edition, the 68th China (Guangzhou) International Beauty Expo, is scheduled for September 4-6, 2025, in Guangzhou [6]